DUBLIN–(BUSINESS WIRE)–The “Large Molecule Bioanalytical Testing Services Market Size, Share & Trends Analysis Report by Phase (Preclinical, Clinical), by Test Type (ADME, PD), by End-user, by Type, by Therapeutic Areas, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.
The global large molecule bioanalytical testing services market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 9.1% over the forecast period. The increased use of bioanalytical testing in clinical trials of biomarkers, large molecules, and other substances is the main driver of the industry.
The rising incidence of chronic diseases and the rising demand for clinical trials in developing nations are the factors driving the market growth. For instance, according to the WHO, around 10 million people died from cancer in 2020. As per the estimates of cancer, 30.2 million people are likely to have cancer by 2040. Other factors that are anticipated to drive the segment growth include a rise in biologics, high demand for advanced technologies, and the need for personalized orphan drugs & medicines.
It is also projected that factors like technological advancement, globalization of clinical trials, and the rising need for CROs to perform clinical trials will accelerate industry expansion. Large pharmaceutical and bioanalytical firms, however, encountered difficulties as a result of the COVID-19 pandemic, which hampered clinical studies and treatments. Along with the workload of the COVID-19 project, which involves starting clinical trials, preclinical testing, doing bioanalysis, and interacting with regulatory bodies, other difficulties include the loss of workers at sites. The non-Covid initiatives were delayed, and there were lengthy 4-6 month wait times as a result of the resources being used to support the bioanalytical, preclinical, and clinical testing for the Covid trials. They must also resolve assays that are related to Covid and those that are not.
Large Molecule Bioanalytical Testing Services Market Report Highlights
The clinical segment dominated the global industry in 2021. The growing prevalence of chronic diseases and increasing demand for clinical trials in developing countries are factors expected to drive segment growth
The ADA-type segment dominated the global industry in 2021 and accounted for the largest share of the overall revenue
Bioavailability was the largest test segment share in 2021 on account of the increasing adoption in generic drug manufacturing
The oncology segment held the largest revenue share in 2021 due to the increasing prevalence of cancer globally
Asia Pacific is projected to witness the fastest CAGR during the forecast years due to the rising healthcare expenditure, particularly in India and China
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Large Molecule Bioanalytical Testing Services Market Variables, Trends & Scope
Chapter 4. Large Molecule Bioanalytical Testing Services Market: Phase Estimates & Trend Analysis
Chapter 5. Large Molecule Bioanalytical Testing Services Market by Type Estimates & Trend Analysis
Chapter 6. Large Molecule Bioanalytical Testing Services Market: Test Type Estimates & Trend Analysis
Chapter 7. Large Molecule Bioanalytical Testing Services Market by Therapeutic Areas Estimates & Trend Analysis
Chapter 8. Large Molecule Bioanalytical Testing Services Market by End – user Estimates & Trend Analysis
Chapter 9. Large Molecule Bioanalytical Testing Services Market: Regional Estimates & Trend Analysis
Chapter 10. Competitive Landscape
Companies Mentioned
Covance
Iqvia
Syneous Health
Sgs, Sa
Toxikon
Intertek plc
Pace Analytical Services LLC
Icon plc
Charles River Laboratories
Thermofisher Scientific
For more information about this report visit https://www.researchandmarkets.com/r/4l6a74
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
